Connect with us

Medical Discovery

2018 Demystifying Medicine: Brave New World: Imaging from the Cosmos to the Molecule

Published

on



2018 Demystifying Medicine: Brave New World: Imaging from the Cosmos to the Molecule

Air date: Tuesday, March 13, 2018, 4:00:00 PM

Category: Demystifying Medicine

Runtime: 01:50:58

Description: Demystifying Medicine Lecture Series

John Mather is the co-recipient of the 2006 Nobel Prize in Physics for his work in detecting the remnant radiation from the birth of the universe, called the cosmic microwave background, which strongly supported the “big bang” theory and which physicist Stephen Hawking described as “the most important discovery of the century, if not of all time.” Mather now is project scientist for the James Webb Space Telescope (JWST), the planned successor to the Hubble Space Telescope.

Lippincott-Schwartz was chief of the NICHD Section on Organelle Biology before moving to the Janelia Research Campus in 2016. Her NIH lab hosted and provided the biological materials to Eric Betzig, who worked with Lippincott-Schwartz, George Patterson (now at NIBIB) and others to develop photoactivation localization microscopy (PALM), which ultimately earned Betzig the 2014 Nobel Prize in Chemistry.

The Demystifying Medicine Lecture Series is designed to help bridge the gap between advances in biology and their applications to major human diseases. The lectures include presentations of patients, pathology, diagnosis, and therapy in the context of major diseases and current research. All clinicians, trainees including fellows, medical students, Ph.D. students, and other healthcare and research professionals are welcome to attend.

For more information go to

Author: John Mather, PhD, Nobel Prize in Physics, National Aeronautics and Space Administration (NASA) and Jennifer Lippincott-Schwartz, PhD, MS, HHMI, Janelia Research Campus

Permanent link:

Medical Discovery

IDZ Weekly | Deep Neural Network Acceleration for Image Analysis in Drug Discovery | Intel Software

Published

on

By



Learn about a recent collaboration with Novartis Pharmaceuticals, which utilizes a deep neural network to accelerate image analysis in early drug discovery by detecting and targeting exactly which cells in the body need treatment.

Read the article:

Keep up to date with the IDZ Weekly Youtube Playlist:

Subscribe to the Intel Software YouTube Channel:

About Intel Software:
The Intel® Developer Zone encourages and supports software developers that are developing applications for Intel hardware and software products. The Intel Software YouTube channel is a place to learn tips and tricks, get the latest news, watch product demos from both Intel, and our many partners across multiple fields. You’ll find videos covering the topics listed below, and to learn more, you can follow the links provided!

Connect with Intel Software:
Visit INTEL SOFTWARE WEBSITE:
Like INTEL SOFTWARE on FACEBOOK:
Follow INTEL SOFTWARE on TWITTER:

INTEL SOFTWARE GITHUB:
INTEL DEVELOPER ZONE LINKEDIN:
INTEL DEVELOPER ZONE INSTAGRAM:
INTEL GAME DEV TWITCH:

IDZ Weekly | Deep Neural Network Acceleration for Image Analysis in Drug Discovery | Intel Software

Continue Reading

Medical Discovery

Virtual Recap Preview: Stanford Drug Discovery Symposium 2018 – Joao Monteiro, MD, PhD

Published

on

By



Virtual Recap: Stanford Drug Discovery 2018
Learn more:

On April 23-24,2018 over 550 people gathered at the Li Ka Shing Conference Center to attend the Third Annual Stanford Drug Discovery Symposium. The event featured a broad range of speakers sharing their expertise in the fields of: academic drug discovery, academic-industry collaboration, science policy, publishing, and research funding. On the first day, the packed-house audience was treated to presentations from academic scientists engaged in groundbreaking research that is laying the foundation for future therapeutic approaches. These included Stanford based Nobel Laureate Brian Kobilka, MD and Edgar Engleman, MD; Kathleen Giacomini, PhD, and Kevan Shokat, PhD from UCSF; and Hugh Rosen, MD, PhD, from the Scripps Research Institute.

Later that afternoon, attendees had the rare opportunity to interact with six top pharmaceutical executives and philanthropists: Ken Frazier, CEO of Merck; Robert Bradway, CEO of Amgen; Joseph Jimenez, former CEO of Novartis; Brent Saunders, CEO of Allergan; Patrick Soon-Shiong, MD, CEO of Nantworks; and Sanford Weill, the Chairman Emeritus of Citigroup and CEO of Casa Rosa Ventures. In this “View from the Top” session moderated by Stanford President Marc Tessier-Lavigne, PhD, the panelists offered their perspectives on drug discovery, including: the future of personalized medicine, the importance of focusing on disease prevention rather than treatment, and the concept that drug pricing could eventually be based on treatment outcomes. The first day ended with the presentation of a Lifetime Achievement Award to Roy Vagelos, MD, former CEO of Merck and current Board chair of Regeneron. Dr. Vagelos was acknowledged in part for his role in leveraging the power of the pharmaceutical industry to make a major impact on global health. During his term as Merck CEO, he personally committed to providing the drug Ivermectin free of charge to anyone in the world for the treatment of elephantiasis and river blindness, with the latter having been since eradicated in multiple Central and South American countries due to Dr. Vagelos’ efforts.

The second day of the Symposium opened with a Keynote address from Janet Woodcock, MD, the Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA), who provided a look inside the agency’s new drug regulatory program. This was followed by important presentations about funding priorities from Gary Gibbons, MD, the Director of the National Heart, Lung, and Blood Institute (NHLBI), and Maria Millan, MD, President and CEO of the California Institute for Regenerative Medicine (CIRM). Later, the audience was treated to a panel of editors representing the top publications in biomedical science: the New England Journal of Medicine, Nature Medicine, Science, and the Journal of the American Medical Association. The meeting concluded with a dynamic Shark Tank-style session, in which representatives from eight competitively selected start-up biotechnology companies pitched their ideas to a panel of scientists, venture capitalists, and CEOs. The panelists who provided feedback were: George Scangos, PhD (CEO of Vir), Robert Robbins, MD (President of the University of Arizona), Roy Vagelos, MD, Amy Chang, MSEE (CEO of Accompany), Ram Shriram (Founder of Sherpalo), and Wende Hutton, MBA (General Partner, Canaan). The goal of this session was to have this stellar panel identify strengths and weaknesses of the strategies described in each presentation, providing invaluable advice to these budding entrepreneurs.

The organizers of the meeting, Joseph Wu, MD, PhD; Sanjay Malhotra, PhD; Kuldev Singh, MD; Mark Mercola, PhD; and Chaitan Khosla, PhD, are thrilled with the success of this gathering, and are already looking forward to the next iteration, which will be held April 22-23, 2019.

___

Copyright Keystone Symposia, 2018. All rights reserved.

About Keystone Symposia:
Keystone Symposia is a 501(c)(3) nonprofit organization founded in 1972 that convenes 50-60 open, international scientific research conferences each year across the full range of the life sciences – from cardiovascular disease to immunology to neurobiology. The conferences accelerate life science discovery by bringing together and fostering collaboration among the world’s leading and next generation of research scientists.

Visit Keystone Symposia at:

Visit Virtual Keystone Symposia at:

For more videos:

Follow us on Twitter:

Like us on Facebook:

Link to us on LinkedIn:

Outro music:
“Slider” by Blue Dot Sessions (

Continue Reading

Medical Discovery

Virtual Recap Preview: Stanford Drug Discovery Symposium 2018 – Janet Woodcock, MD

Published

on

By



Virtual Recap: Stanford Drug Discovery 2018
Learn more:

On April 23-24,2018 over 550 people gathered at the Li Ka Shing Conference Center to attend the Third Annual Stanford Drug Discovery Symposium. The event featured a broad range of speakers sharing their expertise in the fields of: academic drug discovery, academic-industry collaboration, science policy, publishing, and research funding. On the first day, the packed-house audience was treated to presentations from academic scientists engaged in groundbreaking research that is laying the foundation for future therapeutic approaches. These included Stanford based Nobel Laureate Brian Kobilka, MD and Edgar Engleman, MD; Kathleen Giacomini, PhD, and Kevan Shokat, PhD from UCSF; and Hugh Rosen, MD, PhD, from the Scripps Research Institute.

Later that afternoon, attendees had the rare opportunity to interact with six top pharmaceutical executives and philanthropists: Ken Frazier, CEO of Merck; Robert Bradway, CEO of Amgen; Joseph Jimenez, former CEO of Novartis; Brent Saunders, CEO of Allergan; Patrick Soon-Shiong, MD, CEO of Nantworks; and Sanford Weill, the Chairman Emeritus of Citigroup and CEO of Casa Rosa Ventures. In this “View from the Top” session moderated by Stanford President Marc Tessier-Lavigne, PhD, the panelists offered their perspectives on drug discovery, including: the future of personalized medicine, the importance of focusing on disease prevention rather than treatment, and the concept that drug pricing could eventually be based on treatment outcomes. The first day ended with the presentation of a Lifetime Achievement Award to Roy Vagelos, MD, former CEO of Merck and current Board chair of Regeneron. Dr. Vagelos was acknowledged in part for his role in leveraging the power of the pharmaceutical industry to make a major impact on global health. During his term as Merck CEO, he personally committed to providing the drug Ivermectin free of charge to anyone in the world for the treatment of elephantiasis and river blindness, with the latter having been since eradicated in multiple Central and South American countries due to Dr. Vagelos’ efforts.

The second day of the Symposium opened with a Keynote address from Janet Woodcock, MD, the Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA), who provided a look inside the agency’s new drug regulatory program. This was followed by important presentations about funding priorities from Gary Gibbons, MD, the Director of the National Heart, Lung, and Blood Institute (NHLBI), and Maria Millan, MD, President and CEO of the California Institute for Regenerative Medicine (CIRM). Later, the audience was treated to a panel of editors representing the top publications in biomedical science: the New England Journal of Medicine, Nature Medicine, Science, and the Journal of the American Medical Association. The meeting concluded with a dynamic Shark Tank-style session, in which representatives from eight competitively selected start-up biotechnology companies pitched their ideas to a panel of scientists, venture capitalists, and CEOs. The panelists who provided feedback were: George Scangos, PhD (CEO of Vir), Robert Robbins, MD (President of the University of Arizona), Roy Vagelos, MD, Amy Chang, MSEE (CEO of Accompany), Ram Shriram (Founder of Sherpalo), and Wende Hutton, MBA (General Partner, Canaan). The goal of this session was to have this stellar panel identify strengths and weaknesses of the strategies described in each presentation, providing invaluable advice to these budding entrepreneurs.

The organizers of the meeting, Joseph Wu, MD, PhD; Sanjay Malhotra, PhD; Kuldev Singh, MD; Mark Mercola, PhD; and Chaitan Khosla, PhD, are thrilled with the success of this gathering, and are already looking forward to the next iteration, which will be held April 22-23, 2019.

___

Copyright Keystone Symposia, 2018. All rights reserved.

About Keystone Symposia:
Keystone Symposia is a 501(c)(3) nonprofit organization founded in 1972 that convenes 50-60 open, international scientific research conferences each year across the full range of the life sciences – from cardiovascular disease to immunology to neurobiology. The conferences accelerate life science discovery by bringing together and fostering collaboration among the world’s leading and next generation of research scientists.

Visit Keystone Symposia at:

Visit Virtual Keystone Symposia at:

For more videos:

Follow us on Twitter:

Like us on Facebook:

Link to us on LinkedIn:

Outro music:
“Slider” by Blue Dot Sessions (

Continue Reading

Trending